NEW YORK (GenomeWeb News) – Genomics-based prostate cancer test developer GenomeDx Biosciences today said that it closed a Series B financing round.

The San Diego-based company declined to disclose the amount raised. Merck Global Health Innovation Fund led the round and was joined by Baird Capital Partners, Aeris Capital, and CD Ventures. The funding will go toward expanding the commercialization of GenomeDx's Decipher prostate cancer test, which predicts the risk of developing the disease independent of a PSA test and other commonly used assessment tools.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.